167
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia

, , , , , , & show all
Pages 184-191 | Received 30 Oct 2013, Accepted 07 Dec 2013, Published online: 21 Jan 2014

References

  • Ohlsen R, Gaughran F. Schizophrenia: a major risk factor for cardiovascular disease. Br J Card Nurs 2011;6: 1–6.
  • De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S. Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatr 2011;10:52–77.
  • De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, van Winkel R, Mitchell AJ. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011; 199:99–105.
  • Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol 2013;3:33–51.
  • Maritim AC, Sanders RA, Watkins JB III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24–38.
  • Zhang M, Zhao Z, He L, Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 2010; 53:112–24.
  • Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996;55:45–54.
  • Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 2006;32:244–52.
  • Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000;28:1815–26.
  • Girotti MJ, Khan N, McLellan BA. Early measurement of systemic lipid peroxidation products in plasma of major blunt trauma patients. J Trauma 1991;31:32–5.
  • Misra H, Fridovich I. Chemistry and metabolism of substances of low molecular weight: the role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;247:3170–5.
  • Ellman GI. Tissue sulfhydril groups. Arc Biochem Biophys 1952;82:70–7.
  • Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37: 277–85.
  • Alamdari DH, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G. A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 2007;40:248–54.
  • Bland JM, Altman DG. Statistics notes: transformations, means, and confidence intervals. BMJ 1996;312:1079.
  • Kraemer HC, Morgan GA, Leech NL, Gliner JA, Vaske JJ, Harmon RJ. Measures of clinical significance. J Am Acad Child Adolesc Psychiatry 2003;42:1524–9.
  • Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Hosmer DW, Lemeshow S (eds). Applied logistic regression New York: John Wiley & Sons, 2000: 143–202.
  • Chang SC, Lu ML. Metabolic and cardiovascular adverse effects associated with treatment with antipsychotic drugs. J Exp Clin Med 2012;4:103–7.
  • Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546–51.
  • Boskovic M, Vovk T, Kores Plesnikar B, Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011;9: 301–12.
  • Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11: 851–76.
  • Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011;35: 878–93.
  • Michel TM, Thome J, Martin D, Nara K, Zwerina S, Tatschner T, Weijers HG, Koutsilieri E. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transm 2004;111: 1191–201.
  • Ciobica A, Padurariu M, Dobrin I, Stefanescu C, Dobrin R. Oxidative stress in schizophrenia-focusing on the main markers. Psychiatria Danubina 2011;23:237–45.
  • Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003;121:109–22.
  • Grignon S, Chianetta JM. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Progr Neuro Psychopharmacol Biol Psychiatr 2007;31:365–9.
  • Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010;479:317–20.
  • Di Mascio P, Murphy ME, Sies H. Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols. Am J Clin Nutr 1991;53:194S–200S.
  • Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?Lancet 1994;344:721–4.
  • Prakash M, Shetty MS, Tilak P, Anwar N. Total thiols: biomedical importance and their alteration in various disorders. Online J Health Allied Scs 2009;8:2.
  • Huang TL, Liou CW, Lin TK. Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: effects of antipsychotic drugs. Psychiatr Res 2010; 177:18–21.
  • Dietrich-Muszalska A, Olas B, Głowacki R, Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 2009;59:1–7.
  • Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Psychiatr 2009;48:60–70.
  • Kurt E, Murat Emül H, Timuçin Oral E. Do atypical antipsychotics strengthen the antioxidant system?Dusunen Adam: J Psychiatry Neurol Sci 2008;21:38–44.
  • Korkamaz GG, Altinoglu E, Civelelek S, Sozer V, Erdenen F, Tabak O, Uzun H. The association of oxidative stress markers with conventional risk factors in the metabolic syndrome. Metabolism 2013;62:828–35.
  • Alamdari DH, Ghayour-Mobarhan M, Tavallaie S, Parizadeh MR, Moohebati M, Ghafoori F, Kazemi-Bajestani SM, Paletas K, Pegiou T, Koliakos G. Prooxidant-antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem 2008;41: 375–80.
  • Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003;37:43–51.
  • Zhang XY, Tan YL, Cao LY. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006;81:291–300.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.